Abstract
The majority of melanoma cells do not express argininosuccinate synthetase (ASS), and hence cannot synthesize arginine from citrulline. Their growth and proliferation depend on exogenous supply of arginine. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death while normal cells which express ASS can survive. This notion has been translated into clinical trial. Pegylated ADI (ADI-PEG20) has shown antitumor activity in melanoma. However, the sensitivity to ADI is different among ASS(-) melanoma cells. We have investigated and reviewed the signaling pathways which are affected by arginine deprivation and their consequences which lead to cell death. We have found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF. These changes most likely lead to autophagy, a possible mechanism to survive by recycling intracellular arginine. However apoptosis does occur which can be both caspase-dependent or independent. In order to increase the therapeutic efficacy of this form of treatment, one should consider adding other agent(s) which can drive the cells toward apoptosis or inhibit the autophagic process.
Keywords: Arginine deiminase, argininosuccinate synthetase, melanoma
Current Molecular Medicine
Title: Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Volume: 10 Issue: 4
Author(s): N. Savaraj, M. You, C. Wu, M. Wangpaichitr, M.T. Kuo and L.G. Feun
Affiliation:
Keywords: Arginine deiminase, argininosuccinate synthetase, melanoma
Abstract: The majority of melanoma cells do not express argininosuccinate synthetase (ASS), and hence cannot synthesize arginine from citrulline. Their growth and proliferation depend on exogenous supply of arginine. Arginine degradation using arginine deiminase (ADI) leads to growth inhibition and eventually cell death while normal cells which express ASS can survive. This notion has been translated into clinical trial. Pegylated ADI (ADI-PEG20) has shown antitumor activity in melanoma. However, the sensitivity to ADI is different among ASS(-) melanoma cells. We have investigated and reviewed the signaling pathways which are affected by arginine deprivation and their consequences which lead to cell death. We have found that arginine deprivation inhibits mTOR signaling but leads to activation of MEK and ERK with no changes in BRAF. These changes most likely lead to autophagy, a possible mechanism to survive by recycling intracellular arginine. However apoptosis does occur which can be both caspase-dependent or independent. In order to increase the therapeutic efficacy of this form of treatment, one should consider adding other agent(s) which can drive the cells toward apoptosis or inhibit the autophagic process.
Export Options
About this article
Cite this article as:
Savaraj N., You M., Wu C., Wangpaichitr M., Kuo M.T. and Feun L.G., Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791316995
DOI https://dx.doi.org/10.2174/156652410791316995 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oleanolic Acid Derived from Plants: Synthesis and Pharmacological Properties of A-ring Modified Derivatives
Letters in Drug Design & Discovery Subject Index to Volume 5
Current Drug Targets Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Production of Alpha Emitters for Targeted Alpha Therapy
Current Radiopharmaceuticals Contrast-enhanced Ultrasound for Liver Imaging: Recent Advances
Current Pharmaceutical Design Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Targeting of Melanoma Cells Using Neural Stem Cells Expressing Carboxylesterase, a CPT-11 Activating Enzyme
Current Stem Cell Research & Therapy Role of α -Crystallin B in Regulation of Stress Induced Cardiomyocyte Apoptosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response
Current Pharmaceutical Design From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Fullerenes for Applications in Biology and Medicine
Current Medicinal Chemistry Nanotechnology and Animal Health
Pharmaceutical Nanotechnology Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Glucose Transporters in Sex Steroid Hormone Related Cancer
Current Vascular Pharmacology Role of Plasmacytoid Dendritic Cells in Lung-Associated Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery